<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00384475</url>
  </required_header>
  <id_info>
    <org_study_id>BY9010/M1-413</org_study_id>
    <nct_id>NCT00384475</nct_id>
  </id_info>
  <brief_title>A Study of Ciclesonide Nasal Spray in Patients 18 Years and Older With Seasonal Allergic Rhinitis (BY9010/M1-413)</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Parallel-group Study Using the Environmental Exposure Chamber (EEC) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray (200 mcg, Once Daily), in the Treatment of Seasonal Allergic Rhinitis (SAR) in Patients 18 Years and Older</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety and effectiveness of ciclesonide nasal&#xD;
      spray as compared with placebo (inactive substance) nasal spray in relieving symptoms of&#xD;
      seasonal allergic rhinitis caused by pollen. Ciclesonide will be administered once during the&#xD;
      exposure to ragweed pollen in a controlled environment. The study duration consists of a&#xD;
      baseline period (up to 5 days) and a treatment period (1 day). The study will provide further&#xD;
      data on safety and tolerability of ciclesonide.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">January 2007</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Onset of action, measured by change from baseline in Total Nasal Symptom Score.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>changes in symptoms, safety.</measure>
  </secondary_outcome>
  <enrollment>500</enrollment>
  <condition>Rhinitis, Allergic, Seasonal</condition>
  <condition>Hay Fever</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciclesonide Nasal Spray</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  General good health&#xD;
&#xD;
          -  History of SAR to short ragweed pollen for 2 years immediately preceding the study&#xD;
&#xD;
          -  Demonstrated sensitivity to short ragweed known to induce SAR through a standard skin&#xD;
             prick test&#xD;
&#xD;
        Main Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant physical finding of nasal anatomical deformities causing&#xD;
             greater than 50% obstruction, including but not limited to nasal polyps, septal&#xD;
             defects, respiratory tract malformations, nasal trauma or surgery&#xD;
&#xD;
          -  Known hypersensitivity to any corticosteroid&#xD;
&#xD;
          -  History of a respiratory infection or disorder including but not limited to&#xD;
             bronchitis, pneumonia, chronic sinusitis, influenza or SARS (severe acute respiratory&#xD;
             syndrome) within 14 days preceding the Screening Visit&#xD;
&#xD;
          -  History of alcohol or drug abuse within 2 years preceding the Screening Visit&#xD;
&#xD;
          -  Active asthma requiring treatment of inhaled or systemic corticosteroids and/or&#xD;
             routine use of beta-agonists or any controller drugs&#xD;
&#xD;
          -  Use of antibiotic therapy for acute conditions within 14 days preceding the Screening&#xD;
             Visit&#xD;
&#xD;
          -  Exposure to systemic corticosteroids for any indication, chronic or intermittent&#xD;
             within 60 days preceding the Screening Visit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AstraZeneca AstraZeneca</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Altana Pharma/Nycomed</name>
      <address>
        <city>Ontario, Mississauga</city>
        <zip>L4W 1N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=4538&amp;filename=BY9010-M1-413-RDS-2007-06-05.pdf</url>
    <description>BY9010-M1-413-RDS-2007-06-05.pdf</description>
  </link>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>October 5, 2006</study_first_submitted>
  <study_first_submitted_qc>October 5, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2006</study_first_posted>
  <last_update_submitted>November 29, 2016</last_update_submitted>
  <last_update_submitted_qc>November 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Seasonal Allergic Rhinitis</keyword>
  <keyword>Ciclesonide</keyword>
  <keyword>Hay Fever</keyword>
  <keyword>SAR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciclesonide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

